BOXR-1030 is under clinical development by SOTIO Biotech and currently in Phase II for Squamous Cell Carcinoma. According to GlobalData, Phase II drugs for Squamous Cell Carcinoma does not have sufficient historical data to build an indication benchmark PTSR for Phase II. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the BOXR-1030 LoA Report. Buy the report here.

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

BOXR-1030 overview

BOXR-1030 is under development for the treatment of hepatocellular carcinoma, lung squamous cell carcinoma, myxoid liposarcoma, round cell liposarcoma, merkel cell carcinoma (MCC), squamous cell carcinoma (SCC) of the lung and other solid tumors. These comprise T-cells modified to express the antigen-specific receptor (to target cancer cells) and a transgene to modify tumor microenvironment. It act by targeting Glypican 3 (GPC3). The drug candidate is developed based on the Bolt-on chimeric receptor (BOXR) technology. It is administered through intravenous route.

SOTIO Biotech overview

SOTIO Biotech (Sotio), a subsidiary of PPF Group NV, is a biotechnology company that develops immunotherapies for cancer treatment. It also evaluates IL-15, superagonist-based programs to develop immunotherapies in oncology. Sotio utilizes its proprietary BOXR cell therapy platform to design and develop engineered T cells by identifying novel bolt-on transgenes in the solid tumor microenvironment. The company is investigating SOT201, an immunocytokine fusing a proprietary IL-15 superagonist to an anti-PD-1 antibody; and BOXR1030, CART T cell therapy against hepatocellular carcinoma and squamous cell carcinoma. The company has operations in Switzerland, the Czech Republic, the Netherlands, and the US. Sotio is headquartered in Prague, North Bohemian, the Czech Republic.

For a complete picture of BOXR-1030’s drug-specific PTSR and LoA scores, buy the report here.

Data Insights

From

The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.

GlobalData

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.